CAMBRIDGE, England--(BUSINESS WIRE)--Varsity Pharmaceuticals (Varsity), a biopharmaceutical company developing small molecule therapies that target treatment resistant cancers, today announced that it has secured exclusive rights from Dana-Farber Cancer Institute, a world-leading cancer treatment and research institute, to develop and commercialize Novobiocin, a potential first-in-class DNA polymerase theta inhibitor for the treatment of Homologous Recombination (HR) deficient cancers.